Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from ...

Embecta expects between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs. Embecta expects between $35 million and $45 million in pre-tax ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now discontinuing its patch pump program as part of a broader restructuring and ...

Embecta is shifting from a "stand-up" to a "seed growth" phase, prioritizing stabilization of its core insulin-delivery franchise, selective portfolio expansion, and brand transition (now >95% of U.S.

In 2022, embecta was spun off from Becton, Dickinson and Company (BD), and BD-branded pen needles and insulin syringes became part of the embecta portfolio. In 2025, the packaging was updated in North ...

Embecta Corp., a spinoff from Becton Dickinson, shows signs of turning around, despite expected earnings declines in fiscal 2024 and 2025. This major player in diabetes management, has a history of ...

CEO Dev Kurdikar emphasized three strategic priorities shaping Embecta’s transformation: strengthening the core business, expanding the product portfolio, and increasing financial flexibility. He ...

Embecta Corp. misses on earnings expectations. Reported EPS is $0.3497 EPS, expectations were $0.45. EMBC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see ...

embecta Corp. (embecta) (Nasdaq: EMBC), a global diabetes care company, visits the Nasdaq MarketSite in Times Square today in recognition of National Diabetes Awareness Month in November. embecta ...

PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced ...